[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337729-105":59,"doc-detail-337729-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","abrogation-of-klf5-sensitizes-brca1-proficient-pancreatic-cancer-to-parp-inhibition","Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition","","Poly ADP-ribose polymerase (PARP) inhibitor monotherapies show selective efficacy in cancers such as pancreatic, breast, prostate, and ovarian when BRCA1 is mutated. Patients with more frequent wild-type BRCA have poor responses, and even initially sensitive cases often develop drug resistance. This study shows that KLF5 abrogation suppresses homologous recombination and increases olaparib-induced DNA damage, lowering the IC50 in pancreatic cancer cells. BRCA1 overexpression reverses these effects and a combination of olaparib with a KLF5 inhibitor enhances cytotoxicity, identifying BRCA1 as a KLF5 target.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/abrogation-of-klf5-sensitizes-brca1-proficient-pancreatic-cancer-to-parp-inhibition/337729/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/abrogation-of-klf5-sensitizes-brca1-proficient-pancreatic-cancer-to-parp-inhibition/337729.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are PARP inhibitors less effective in pancreatic cancer patients with wild-type BRCA1/2?","Question",{"text":113,"@type":114},"PARP inhibitors provide limited clinical benefit for most pancreatic cancer patients with wild-type BRCA1/2, which limits their applicability beyond BRCA-mutated subsets.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What effect does KLF5 abrogation have on DNA repair and PARP inhibitor sensitivity?",{"text":118,"@type":114},"Abrogation of KLF5 significantly inhibits homologous recombination, increases DNA damage induced by olaparib, and reduces the IC50 of PARP inhibition in pancreatic cancer cells.",{"name":120,"@type":111,"acceptedAnswer":121},"How does BRCA1 relate to KLF5 in the study’s mechanism?",{"text":122,"@type":114},"BRCA1 is identified as a KLF5 target gene, and BRCA1 overexpression reverses the effects caused by KLF5 silencing; BRCA1 is positively correlated with KLF5 in PDAC tissue.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},337729,1790696395,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Original Article  \nAbrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition  \nZheng Zhang 1,2,3,†, Yuxin Liu4,†, Yaolin Xu 1,2,3, Zijin Xu5, Jinbin Jia4, Yun Jin6, Wenquan Wang 1,2,3, *, and Liang Liu 1,2,3, *  \n1 Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China, 2Cancer Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China, 3Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China, 4 Institute of Liver Diseases, Shanxi Medical University, Taiyuan 030001, China, 5Department of General Surgery, Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University, Shanghai, 201700, China, and 6 Department of Hepatobiliary and Pancreatic Surgery, the First People’s  \nHospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming 650500, China †These authors contributed equally to this work.  \n*Correspondence address. Tel: +86-21-64041990; E-mail: [liu.liang@zs-hospital.sh.cn](liu.liang@zs-hospital.sh.cn) (L. L. ) / [E-mail:](E-mail: wang.wenquan@zs-hospital.sh.cn)[ wang.wenquan@zs-hospital.sh.cn](E-mail: wang.wenquan@zs-hospital.sh.cn) (W.W. ) Received 17 August 2023 Accepted 14 December 2023  \nAbstract  \nPoly ADP-ribose polymerase (PARP) inhibitor monotherapies are selectively effective in patients with pancreatic, breast, prostate, and ovarian cancers with BRCA1 mutations. Cancer patients with more frequent wild-type BRCA show poor responsesto PARP inhibitors. Moreover, patients who are initially sensitive to these inhibitors eventually respond poorly to drugs. In the present study, we discover that abrogation of Kruppel-like factor 5 (KLF5) significantly inhibits homologous recombination, which is the main mechanism for DNA double-stranded repair. Furthermore, the downregulation of KLF5 expression promotes the DNA damage induced by olaparib and significantly reduces the IC50 of the RARP inhibitor in pancreatic cancer cells. Overexpression of BRCA1 reverses the above effects caused by silencing of KLF5. Olaparib combined with a KLF5 inhibitor has an enhanced cytotoxic effect. Mechanistically, we identify BRCA1 as a KLF5 target gene. BRCA1 is positively correlated with KLF5 in PDACtissue. Our results indicate that inhibition of KLF5 may induce BRCAness in a larger pancreatic cancer subset with proficient BRCA. The combination of KLF5 inhibitors and PARP inhibitors provides a novel treatment strategy to enhance the sensitivity of BRCA1-proficient pancreatic cancer to PARP inhibitors.  \nKey words pancreatic cancer, wild-type BRCA, BRCAness, KLF5, BRCA1  \nIntroduction  \nThere were 466,003 cancer-related deaths and 495,773 new cases of pancreatic cancer (PC) worldwide in 2020 [1] . It is urgent to develop novel treatment strategies beyond surgery and traditional chemotherapy. Strickler et al. [2] demonstrated that patients pretreated with KRAS p. G12C-mutated advanced PC responded robustly to sotorasib and showed good tolerance [2] . Pembrolizumab is recommended for unresectable or metastatic pancreatic ductaladenocarcinomas (PDAC) harboring defective DNA mismatchrepair-deficiency or microsatellite instability-high, which occur in 1%‒2% of PDAC cases. The PARP inhibitor olaparib has been approved for maintenance treatment of pretreated patients with metastatic PDAC with a germline BRCA mutation (4%‒7% of PDAC) [3] . However, PARP inhibitors confer little clinical benefit to  \nmost pancreatic cancer patients with wild-type BRCA1/2 . Therefore, it is urgent to develop a novel strategy for expanding PARP inhibitors to BRCA-proficient PC.  \nKrüppel-factor 5 (KLF5) is a member of the KLF family and acts asa transcription factor that is frequently overexpressed in cancers [4] . KLF5 often functions as an oncogenic protein by regulating multiple target genes, such as Slug [5], p27 [6], and Cyclin D1 [7], thus regulating cell migration and proliferation. Hence, the upregulati","cbCairhbjVNFplxS","https://ap.wps.com/l/cbCairhbjVNFplxS","pdf",2195303,"English","# Abstract\n## Introduction","[{\"question\":\"Why are PARP inhibitors less effective in pancreatic cancer patients with wild-type BRCA1/2?\",\"answer\":\"PARP inhibitors provide limited clinical benefit for most pancreatic cancer patients with wild-type BRCA1/2, which limits their applicability beyond BRCA-mutated subsets.\"},{\"question\":\"What effect does KLF5 abrogation have on DNA repair and PARP inhibitor sensitivity?\",\"answer\":\"Abrogation of KLF5 significantly inhibits homologous recombination, increases DNA damage induced by olaparib, and reduces the IC50 of PARP inhibition in pancreatic cancer cells.\"},{\"question\":\"How does BRCA1 relate to KLF5 in the study’s mechanism?\",\"answer\":\"BRCA1 is identified as a KLF5 target gene, and BRCA1 overexpression reverses the effects caused by KLF5 silencing; BRCA1 is positively correlated with KLF5 in PDAC tissue.\"}]","Abrogation of KLF5 sensitizes BRCA1-proficient pancreatic cancer to PARP inhibition | PDF",1790020382,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e53c8e57f121e0c81cd58f84e3bf2ba.webp",983,1269,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b4951c8a0f0d775382e04ac35644d20.webp",982,1268,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ef24d041c87a18600353435e25c4217.webp",981,1266,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9247f6b617bf8f3f123c041b13d2fae1.webp",980,1265]